METHOD FOR SELECTING A HIGH EXPRESSION RECOMBINANT CELL LINE

The present invention relates to a method of selecting high producer clones by using an expression vector, the expression vector comprising: (i) a gene expression cassette comprising a selectable marker gene to which polyA has been inoperably linked; and (ii) a gene expression cassette which encodes a recombinant protein of interest and to which polyA has been operably linked. According to the invention, high producer clones can be selected from cell populations at least 10 times fewer than in the existing methods of selecting cell lines. Particularly, high producer clones can be selected using a low concentration of MTX compared to a conventional stepwise gene amplification strategy which comprises carrying out multiple amplification steps while increasing the concentration of MTX. Accordingly, the development period of cell lines can be shortened and the labor and cost required for selection of high-productivity cell clones can be reduced, whereby more efficient production of proteins is possible even when general selectable marker genes other than MTX are used. 1. A method of selecting high producer clones by using an expression vector , the expression vector comprising: (i) a gene expression cassette comprising a selectable marker gene to which a polyadenylation signal (polyA) has been inoperably linked; and (ii) a gene expression cassette which encodes a recombinant protein of interest and to which polyA has been operably linked.2. The method of claim 1 , wherein the expression vector comprises claim 1 , in place of the gene expression cassette (i) containing the selectable marker gene to which the polyA has been inoperably linked claim 1 , a gene expression cassette comprising a selectable marker gene from which polyA has been removed.3. A method for selecting high producer clones claim 1 , the method comprising cleaving an expression vector with a restriction enzyme claim 1 , the expression vector comprising (i) a gene expression cassette comprising a ...

BUCKLE AND METHOD FOR PREVENTING THE BUCKLE FROM BEING RELEASED BY AN IMPACT

The present invention relates to a buckle including a frame, a tongue inserted into the frame and locked with the frame, an ejector provided in the frame to push the tongue outward from the frame, a holder that prevents the ejector from pushing the tongue outward from the frame by being displaced forward the ejector, thereby maintaining locking of the tongue, and a withdrawal prevention unit that prevents the holder from moving back beyond withdrawing and being displaced backward the ejector when an impact is applied from an outside of the frame, thereby preventing the locking of the tongue from being released by the impact. 1. A buckle comprising:a frame;a tongue inserted into the frame and locked with the frame;an ejector provided in the frame to push the tongue outward from the frame;a holder that prevents the ejector from pushing the tongue outward from the frame by being displaced forward the ejector, thereby maintaining locking of the tongue; anda withdrawal prevention unit that prevents the holder from withdrawing and being displaced backward the ejector when an impact is applied from an outside of the frame, thereby preventing the locking of the tongue from being released by the impact,wherein the withdrawal prevention unit comprises:a body has a substantially reverse L shape, the pivot point of the body is located at a spot at which a curved structure is formed, a first end of the body is disposed to face the holder, and a second end is provided with a balance weight such that the pivot point and the center of gravity of the body are spaced from each other and is disposed opposite to the first end about the pivot point with the first end facing the second end to pivot toward the holder by means of a moment generated; andan elastic member provided between the body and the holder to apply an expansion force to the body and the holder, thereby preventing the body from interrupting withdrawal of the holder when an impact is not applied from an outside of the ...

Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses

The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection.

METHOD TO IMPROE THE SORBENT EFFICIENCY OF PROTEIN A CHROMATOGRAPHY USING SWITCHING COLUMN WITH CONTINUOUS FEEDING

The present invention relates to a method to improve the sorbent efficiency of protein A chromatography using switching column with continuous feeding. In the chromatography method of the present invention, the increased usage efficiency of the absorbent (resin), the decreased processing time, the decreased operation cycle of column compared to that of single batch-type column, and the reduced amount of used resin are achieved and thus, the target protein can be purified at a high efficiency and a low cost. 14-. (canceled)5. A method of purifying a target protein using the chromatography apparatus including two columns , which comprises the steps of:1) loading a sample on the first column;2) loading an unabsorbed fluid from the first column, on the second column which is connected to the first column in series;3) after injecting the sample on the first column to the maximum static binding capacity (qm) of the first column, while the target protein is collected from the first column, and the first column is regenerated in a state of being disconnected from the second column, loading the sample on the second column;4) after the regeneration of the first column in step 3) is completed, loading an unabsorbed fluid from the second column on the first column by connecting the second column to the first column in series;5) after injecting the sample on the second column to the maximum static binding capacity (qm) of the second column, while the target protein is collected from the second column and the second column is regenerated in a state of being disconnected from the first column, loading the sample on the first column; and6) operating the steps 1) to 5) repetitively until the complete consumption of the sample.67-. (canceled)8. The method of claim 5 , wherein the target protein is a monoclonal antibody claim 5 , an immunoglobulin claim 5 , or a recombinant protein.9. The method of claim 5 , wherein the column includes a solid phase to be loaded with sample where the ...

LOAD LIMITER

Disclosed is a load limiter mounted within a cylindrical spool on which a webbing is wound to constrain a load applied to the webbing from exceeding a preset load, the load limiter including: a first torsion bar inserted into a hollow portion formed at a center of the spool and one end of which is coupled to one end of the spool; and a second torsion bar one end of which is connected to an opposite end of the first torsion bar to be inserted into the hollow portion of the spool together with the first torsion bar and an opposite end of which is coupled to a locker installed at an opposite end of the spool, wherein the torsion bar is configured such that a torsion load limit of the first torsion bar is smaller than a torsion load limit of the second torsion bar. 1. A load limiter mounted within a cylindrical spool on which a webbing is wound , the load limiter constraining a load applied to the webbing from exceeding a preset load , and comprising: a first torsion bar inserted into a hollow portion formed at a center of the spool , and having one end coupled to one end of the spool; and a second torsion bar inserted into the hollow portion of the spool together with the first torsion bar , and having one end connected to an opposite end of the first torsion bar and an opposite end coupled to a locker installed at an opposite end of the spool , wherein the first torsion bar is configured such that a torsion load limit of the first torsion bar is smaller than a torsion load limit of the second torsion bar.2. The load limiter as claimed in claim 1 , wherein when the one end of the spool is rotated as the webbing continues to be drew and the opposite end of the spool is fixed due to a locking operation of the locker claim 1 , both a torsion load of the first torsion bar and a torsion load of the second torsion bar increase as the load applied to the webbing increases claim 1 , and wherein the increasing load applied to the webbing is constrained from exceeding the preset ...

ADJUVANT COMPOSITION CONTAINING AT LEAST ONE INFLUENZA VIRUS NEUTRALIZING AND BINDING MOLECULE AND VACCINE COMPOSITION CONTAINING SAME

This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses. 19-. (canceled)10. A method of enhancing an immune response to a target antigen , comprising administering a vaccine composition comprising at least one binding molecule for neutralizing an influenza virus and a target antigen to a host.11. A method of preparing an immunological product , comprising:(a) immunizing a host by administering a vaccine composition comprising at least one binding molecule for neutralizing an influenza virus and a target antigen to the host; and(b) obtaining an immunological product from the immunized host, wherein the immunological product is a T cell, a B cell or an antibody against a target antigen comprised in the vaccine composition.12. A method of enhancing an immune response to an influenza A virus in a Subject which comprises administering to the subject a vaccine composition comprising a complex of the influenza A virus and an antibody directed to the influenza A virus.13. The method of claim 12 , wherein the antibody is specifically bound to the influenza A virus and the complex binds to an Fc receptor of immune cells.14. The method of claim 12 , wherein the ratio by weight of the influenza A virus to the antibody directed to the influenza A virus in the complex is between 1:0.02 and 1:200.15. The method of claim 12 , wherein the antibody directed to the influenza A virus bind to at least one epitope selected from the group consisting of i) an epitope comprising an amino acid residue selected from the group consisting of the amino acids at positions 18 claim ...

ADJUVANT COMPOSITION CONTAINING AT LEAST ONE INFLUENZA VIRUS NEUTRALIZING AND BINDING MOLECULE AND VACCINE COMPOSITION CONTAINING SAME

This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses. 1. An adjuvant composition , comprising at least one binding molecule for neutralizing an influenza virus.2. The adjuvant composition of claim 1 , wherein the binding molecule binds to an epitope in a stem region of a hemagglutinin (HA) protein of an influenza A virus.3. The adjuvant composition of claim 1 , wherein an epitope of the binding molecule is at least one selected from the group consisting of i) an epitope comprising any one amino acid residue selected from the group consisting of amino acids at positions 18 claim 1 , 25 claim 1 , 27 claim 1 , 32 claim 1 , 33 claim 1 , 38 claim 1 , 40 claim 1 , 54 claim 1 , 55 claim 1 , 278 claim 1 , 291 claim 1 , 292 claim 1 , 310 claim 1 , 311 claim 1 , 312 and 318 of an HA1 polypeptide; and ii) an epitope comprising any one amino acid residue selected from the group consisting of amino acids at positions 18 claim 1 , 19 claim 1 , 20 claim 1 , 21 claim 1 , 38 claim 1 , 39 claim 1 , 41 claim 1 , 42 claim 1 , 45 claim 1 , 46 claim 1 , 48 claim 1 , 49 claim 1 , 52 claim 1 , 53 claim 1 , 56 claim 1 , 57 claim 1 , 58 claim 1 , 60 and 99 of an HA2 polypeptide.4. The adjuvant composition of claim 1 , wherein the at least one binding molecule is at least one selected from the group consisting of i) a binding molecule claim 1 , comprising a light-chain variable domain including a CDR1 region of SEQ ID NO:1 claim 1 , a CDR2 region of SEQ ID NO:2 and a CDR3 region of SEQ ID NO:3 claim 1 , and a heavy-chain variable domain including a CDR1 region of SEQ ID NO: ...

RABIES VIRUS G PROTEIN EPITOPE, AND RABIES VIRUS NEUTRALISING BINDING MOLECULE THAT BINDS SPECIFICALLY THERETO

This invention relates to a rabies virus G protein epitope and a rabies-virus-neutralizing binding molecule that binds specifically thereto, wherein different epitope sites of rabies virus G protein are identified and binding molecules that bind thereto and a cocktail thereof can be found to retain neutralizing activity against various rabies viruses. 1. A rabies-virus-neutralizing binding molecule that binds to an epitope located between 33to 333amino acid residues of a wild-type rabies virus G protein represented by SEQ ID NO:2.2. The binding molecule of claim 1 , wherein the epitope is an epitope located between 33to 215amino acid residues of the wild-type rabies virus G protein represented by SEQ ID NO:2.3. The binding molecule of claim 2 , wherein the epitope is an epitope comprising at least one selected from the group consisting of 33 claim 2 , 34 claim 2 , 35 claim 2 , 38 claim 2 , 200 claim 2 , 202and 215amino acid residues of the wild-type rabies virus G protein represented by SEQ ID NO:2.4. The binding molecule of claim 2 , wherein the binding molecule has a binding affinity (K) of less than 1×10M.5. The binding molecule of claim 2 , wherein the binding molecule comprises:a) a variable domain comprising a CDR1 of SEQ ID NO:3, a CDR2 of SEQ ID NO:4, and a CDR3 of SEQ ID NO:5; orb) a variable domain comprising a CDR1 of SEQ ID NO:6, a CDR2 of SEQ ID NO:7, and a CDR3 of SEQ ID NO:8.6. The binding molecule of claim 1 , wherein the epitope is an epitope located between 331to 333amino acid residues of the wild-type rabies virus G protein represented by SEQ ID NO:2.7. The binding molecule of claim 6 , wherein the epitope is an epitope comprising at least one selected from the group consisting of 331and 333amino acid residues of the wild-type rabies virus G protein represented by SEQ ID NO:2.8. The binding molecule of claim 6 , wherein the binding molecule has a binding affinity (K) of less than 1×10M.9. The binding molecule of claim 6 , wherein the binding ...

Composition comprising at least two influenza a virus-neutralizing-binding molecules

The present invention provides a composition comprising at least two influenza A virus-neutralizing binding molecules that bind to an epitope in the stem region of influenza A virus hemagglutinin (HA) protein, the method comprising: i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9; ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition of the present invention can effectively neutralize the multiple influenza subtypes of both phylogenetic group 1 and phylogenetic group 2 and can be used in combination with a chemical compound. Thus, the composition of the present invention is very useful for the prevention and treatment of a disease by influenza virus.

Binding Molecule Having Neutralizing Activity Against Middle East Respiratory Syndrome-Coronavirus

The present invention relates to a binding molecule having neutralizing activity against Middle East Respiratory Syndrome-Coronavirus (MERS-CoV). More particularly, the present invention relates to a binding molecule having strong ability to bind to an S protein of MERS-CoV and neutralizing activity against MERS-CoV and thus being very useful in the prevention, treatment or diagnosis of MERS-CoV infection. 1. A neutralizing binding molecule , which binds to a spike protein (S protein) on a surface of a Middle East Respiratory Syndrome-Coronavirus (MERS-CoV).2. The binding molecule of claim 1 , wherein the binding molecule comprises at least one of the binding molecules i) to vi) below:i) a binding molecule comprising a) a heavy-chain variable region comprising a CDR1 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR3 region of SEQ ID NO: 3, and b) a light-chain variable region comprising a CDR1 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO: 5, and a CDR3 region of SEQ ID NO: 6;ii) a binding molecule comprising a) a heavy-chain variable region comprising a CDR1 region of SEQ ID NO: 7, a CDR2 region of SEQ ID NO: 8, and a CDR3 region of SEQ ID NO: 9, and b) a light-chain variable region comprising a CDR1 region of SEQ ID NO: 10, a CDR2 region of SEQ ID NO: 11, and a CDR3 region of SEQ ID NO: 12;iii) a binding molecule comprising a) a heavy-chain variable region comprising a CDR1 region of SEQ ID NO: 13, a CDR2 region of SEQ ID NO: 14, and a CDR3 region of SEQ ID NO: 15, and b) a light-chain variable region comprising a CDR1 region of SEQ ID NO: 16, a CDR2 region of SEQ ID NO: 17, and a CDR3 region of SEQ ID NO: 18;iv) a binding molecule comprising a) a heavy-chain variable region comprising a CDR1 region of SEQ ID NO: 19, a CDR2 region of SEQ ID NO: 20, and a CDR3 region of SEQ ID NO: 21, and b) a light-chain variable region comprising a CDR1 region of SEQ ID NO: 22, a CDR2 region of SEQ ID NO: 23, and a CDR3 region of SEQ ID NO: 24;v) a binding ...

STABLE LIQUID FORMULA

Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible. 1. A liquid formulation , comprising:(A) an antibody or antigen-binding portion thereof;(B) an acetate buffer;(C) glycine; and(D) a surfactant,wherein:the liquid formulation does not comprise sugar nor a sugar alcohol nor a metal salt.2. The liquid formulation of claim 1 , wherein (A) the antibody comprises at least one of infliximab claim 1 , adalimumab claim 1 , certolizumab pegol and golimumab.3. The liquid formulation of claim 1 , wherein (A) the antibody comprises:a light-chain variable region comprising a CDR1 domain comprising an amino acid sequence of SEQ ID NO:1, a CDR2 domain comprising an amino acid sequence of SEQ ID NO:2, and a CDR3 domain comprising an amino acid sequence of SEQ ID NO:3; anda heavy-chain variable region comprising a CDR1 domain comprising an amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising an amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising an amino acid sequence of SEQ ID NO:6.4. The liquid formulation of claim 1 , wherein (A) the antibody has a concentration of 50 to 150 mg/mL.5. The liquid formulation of claim 1 , wherein (B) the acetate buffer has an acetate concentration of 1 to 30 mM.6. The liquid formulation of claim 1 , wherein the liquid formulation does not comprise at least one of histidine claim 1 , citrate claim 1 , phosphate claim 1 , maleate claim 1 , tartrate claim 1 , and succinate.7. The liquid formulation of claim 1 , wherein (C) the glycine has a concentration of 100 to 300 mM.8. The liquid formulation of claim 1 , wherein the liquid formulation does not ...

DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME

The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method of producing the same and anticancer drug composition containing the same as an active ingredient. 2. The dolastatin-10 derivative or a pharmaceutically acceptable salt thereof of claim 1 , wherein{'sub': 1', '3', '4', '1', '4, 'R, Rand Rare each C-Calkyl,'}{'sub': 2', '5', '1', '4, 'Rand Rare each independently hydrogen or C-Calkyl,'}{'sub': 6', '1', '4, 'Ris hydrogen, hydroxy, C-Calkoxy, amino, oxo(═O) or hydroxyimino(═N—OH),'}{'sub': 1', '4', '1', '4, 'Ar is phenyl unsubstituted or substituted with at least one selected from the group consisting of C-Calkyl, C-Calkoxy, and halogen,'}X is a carbon atom, and{'sub': 7', '1', '4', '1', '4, 'Ris hydroxy, amino, C-Calkoxy or C-Calkylamino.'}3. The dolastatin-10 derivative or a pharmaceutically acceptable salt thereof of claim 1 , wherein{'sub': 1', '3', '4, 'R, Rand Rare each methyl,'}{'sub': 2', '5, 'Rand Rare each independently hydrogen or methyl,'}{'sub': '6', 'Ris hydrogen, hydroxy, methoxy, amino, oxo (═O) or hydroxyimino (═N—OH),'}Ar is phenyl unsubstituted or substituted with at least one selected from the group consisting of methyl, methoxy and halogen,X is a carbon atom, and{'sub': '7', 'Ris hydroxy, amino, methoxy, or N-methylamino.'}5. The dolastatin-10 derivative or a pharmaceutically acceptable salt thereof of claim 1 , being selected from the group consisting of:(S)—N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((2,6-difluorophenethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-4-methoxypyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butaneamido)butanamide (I-1);(S)—N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((3-fluorophenethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-4-methoxypyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butaneamido)butanamide (I-2);(S)—N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((4-fluorophenethyl)amino)-1- ...

Stable peptide-conjugated ascorbic acid derivative, method for preparing same, and cosmetic composition comprising same

The present invention provides a stable peptide-conjugated, ascorbic acid derivative, a method for preparing the same, and a cosmetic composition comprising the same as an active ingredient. The stable peptide-conjugated ascorbic acid derivative of the present invention has both the effect of whitening the skin by inhibiting melanin production and the effect of reducing skin wrinkles by activating collagen production, and may be used in a cosmetic composition.

Expression Cassette for Production of High-Expression and High-Functionality Target Protein and Use Thereof

The present invention relates to an expression cassette for a target protein, comprising a promoter, a polynucleotide coding for the target protein, an intron sequence, and a poly A sequence, an expression vector, and a transformant. The expression cassette for a target protein according to the present invention can simultaneously perform the expression of the intron sequence and the target protein through one transduction and exhibits the effect of inducing the high expression and high functionality of the target protein by regulating the expression of an endogenous gene. 1. An expression cassette for production of a target protein , comprising a promoter , a polynucleotide coding for the target protein , an intronic RNA sequence and a poly A sequence , wherein the intronic RNA sequence comprises a splicing donor , a branch and a splicing acceptor.2. The expression cassette for production of a target protein of claim 1 , wherein the target protein is an antibody or a fragment thereof.3. The expression cassette for production of a target protein of claim 1 , wherein at least one intronic RNA sequence is present on a single target protein expression cassette.4. The expression cassette for production of a target protein of claim 1 , wherein the expression cassette for production of a target protein comprises at least one intronic RNA sequence selected from the group consisting of:a) at least one intronic RNA sequence located between a promoter and a polynucleotide coding for the target protein;b) at least one intronic RNA sequence located between a polynucleotide coding for the target protein and a poly A; andc) at least one intronic RNA sequence located between a promoter and a polynucleotide coding for the target protein and at least one intronic RNA sequence located between a polynucleotide coding for the target protein and a poly A.5. The expression cassette for production of a target protein of claim 1 , wherein the intronic RNA sequence further comprises an RNA ...

EPITOPE OF HEPATITIS B VIRUS SURFACE ANTIGEN AND BINDING MOLECULE SPECIFICALLY BINDING TO SAME FOR NEUTRALIZING HAPATITIS B VIRUS

The present invention relates to an epitope specific to hepatitis B virus surface antigen and a binding molecule binding to the same for neutralizing hepatitis B virus. Since the epitope provided by the present invention is produced by forming a three-dimensional structure and does not comprise a determinant, by which escape mutation is induced against an administration of existing vaccines or HBIg, a composition comprising an antibody biding to the epitope or a vaccine composition comprising the epitope has a very low possibility of causing a decrease in efficacy due to escape mutation. Therefore, such an antibody or vaccine composition can be very effectively used in prevention and/or treatment of HBV. 1. An epitope of 3 to 38 mer selected from among amino acids at positions 106-151 of a hepatitis B virus surface antigen (HBsAg).2. The epitope of claim 1 , wherein the epitope is amino acids at positions 106-110 claim 1 , 107-111 claim 1 , 108-112 claim 1 , 109-113 claim 1 , 110-114 claim 1 , 114-118 claim 1 , 115-119 claim 1 , 119-123 claim 1 , 120-124 claim 1 , 143-147 claim 1 , 144-148 claim 1 , 145-149 claim 1 , 146-150 claim 1 , 147-151 claim 1 , 110-118 claim 1 , 118-120 claim 1 , 116-120 claim 1 , 117-121 claim 1 , 118-122 claim 1 , 120-147 claim 1 , 110-120 claim 1 , 118-147 or 110-147 of the hepatitis B virus surface antigen (HBsAg).3. The epitope of claim 1 , wherein the epitope is amino acids at positions 110-120 or 110-147 of the hepatitis B virus surface antigen (HBsAg).4. A binding molecule for neutralizing hepatitis B virus (HBV) claim 1 , which specifically binds to an epitope including at least one amino acid residue selected from the group consisting of amino acids at positions 110 claim 1 , 118 and 120 of a hepatitis B virus surface antigen (HBsAg).5. The binding molecule of claim 4 , wherein the epitope further includes an amino acid at position 147.6. The binding molecule of claim 4 , wherein the binding molecule has a binding affinity of less ...

Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same

The present invention relates to an antibody-linker-drug conjugate in which an antibody and a cytotoxic drug are conjugated through an enzyme cleavable peptide linker capable of directly binding to a lysine residue of an antibody, a preparation method therefor, and an anticancer drug composition containing the same as an active ingredient.

Stable liquid formula

Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

二氯乙酸伊马替尼及含有相同成分的抗癌药剂

本发明涉及二氯乙酸伊马替尼及含有相同成分的抗癌药剂。本发明的二氯乙酸伊马替尼可抑制酪氨酸激酶，并诱导癌细胞通过细胞凋亡杀死自己，从而抑制癌细胞的生长，并导致它们的灭亡，并通过伊马替尼和二氯乙酸的协同作用表现了明显增强的抗癌效果。

Preloader including fracture engagement type tooth bar

根据本发明的包括断裂啮合型齿条的预紧器包括：形成有容纳空间的壳体；小齿轮，其设置在容纳空间中，并且连接至卷绕座位安全带的织带的卷轴的旋转轴以随着卷轴的旋转而进行旋转；微气体发生器，其响应于来自外部的冲撞而生成爆炸力；输送管，其一侧连接至微气体发生器，而在另一侧形成有开口部以连接至容纳空间；多个球形构件，其设置在输送管内，且借助微气体发生器的爆炸力而被输送至容纳空间侧；以及齿条，所述齿条以被固定部固定的状态设置在容纳空间中，其中，借助微气体发生器的爆炸力而被输送到容纳空间侧的球形构件使所述固定部断裂以使所述齿条与小齿轮啮合，且所述齿条借助球形构件的残留推力使小齿轮沿收紧织带的方向旋转。

Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same

The present invention relates to an antibody-linker-drug conjugate in which an antibody and a cytotoxic drug are conjugated through an enzyme cleavable peptide linker capable of directly binding to a lysine residue of an antibody, a preparation method therefor, and an anticancer drug composition containing the same as an active ingredient.

Stable peptide-conjugated ascorbic acid derivatives, process for preparing same and cosmetic compositions containing same

本发明提供稳定的肽缀合抗坏血酸衍生物、用于制备其的方法和包含其作为活性成分的化妆品组合物。本发明的稳定的肽缀合抗坏血酸衍生物具有通过抑制黑色素产生来美白皮肤的效果和通过激活胶原蛋白产生来减少皮肤皱纹的效果，并且可以在化妆品组合物中使用。

Dolastatin-10 derivative, its production process and anticancer drug composition containing the same

Derivado de dolastatina-10, representado por la fórmula química I siguiente: **Fórmula** o sal farmacéuticamente aceptable del mismo, en el/la que R1, R2, R3, R4, y R5 son cada uno independientemente hidrógeno o alquilo de C1-C4, R6 es hidrógeno, hidroxi, alcoxi de C1-C4, amino, oxo (>=O), o hidroxiimino (>=N-OH), Ar es arilo, X es un átomo de carbono, de oxígeno o de azufre, y R7 es hidroxi, amino, alcoxi de C1-C4, alquil C1-C4-amino, u oxo (>=O) cuando X es un átomo de carbono, y está ausente cuando X es un átomo de oxígeno o de azufre.

Epitope of hepatitis b virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis b virus

Composition for alleviating skin inflammation caused by yellow dust and fine particulate, comprising natural plant extract

The present invention relates to a composition comprising natural plant extracts for alleviating inflammation caused by yellow dust and fine particulate, wherein the plant extracts of the present invention inhibit a production of NO caused by the yellow dust and fine particulate and a production of inflammatory cytokines, thus having an excellent effect on preventing or alleviating skin inflammation caused by the yellow dust, fine particulate and other harmful substances.

Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses

The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection.

Composition comprising at least two influenza a virus-neutralizing-binding molecules

The present invention provides a composition comprising at least two influenza A virus-neutralizing binding molecules that bind to an epitope in the stem region of influenza A virus hemagglutinin (HA) protein, the method comprising: i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9; ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition of the present invention can effectively neutralize the multiple influenza subtypes of both phylogenetic group 1 and phylogenetic group 2 and can be used in combination with a chemical compound. Thus, the composition of the present invention is very useful for the prevention and treatment of a disease by influenza virus.

Stable liquid formula

Pretensioner

一种预紧器，用于在从外侧施加冲击时通过由引爆火药获得的爆炸力引入缠绕在卷轴中的织带，所述预紧器包括：中空气缸，具有用于将连接到卷轴上的小齿轮的一部分插入的一个侧表面；微型气体发生器(MGG)，安装在气缸的上端部中，用于在从外侧施加冲击时，提供在内部的火药爆炸的同时，将爆炸力传递到气缸中；齿条，安装在气缸内部的长度方向上，具有朝所述MGG布置的一个端部、与小齿轮相对地布置的另一个端部、以及提供在一个侧表面中的齿轮齿，所述齿轮齿在自MGG接收爆炸力前分离以不与小齿轮啮合；以及辊，用于自MGG接收爆炸力，并以能转动的方式安装在与小齿轮的一部分所插入的气缸的一个侧表面相对的另一个侧表面处，使得当齿条向气缸的下端部落下时，齿条的齿轮齿与小齿轮啮合，并用于引导分离的齿条朝小齿轮移动。

Imatinib dichloroacetate and anti-cancer agent comprising the same

The present invention relates to imatinib dichloroacetate and an anti-cancer agent comprising the same. The imatinib dichloroacetate of the present invention can inhibit tyrosine kinase as well as induce cancer cells to kill themselves via apoptosis, thereby inhibit growth of cancer cells and lead to their destruction, and show significantly enhanced anti-cancer effects by synergy between imatinib and dichloroacetic acid.

Imatinib dichloroacetate and anti-cancer agent comprising the same

本发明涉及二氯乙酸伊马替尼及含有相同成分的抗癌药剂。本发明的二氯乙酸伊马替尼可抑制酪氨酸激酶，并诱导癌细胞通过细胞凋亡杀死自己，从而抑制癌细胞的生长，并导致它们的灭亡，并通过伊马替尼和二氯乙酸的协同作用表现了明显增强的抗癌效果。

EXPRESSION VECTOR FOR ANIMAL CELL CONTAINING AT LEAST ONE COPY OF MAR DNA SEQUENCES AT THE 3 'END OF THE TRANSCRIPTION REFINING RANGE OF A GENE AND METHOD FOR EXPRESSING A FOREIGN AGGREGATION USING THE VECTOR

Whitening cosmetic composition comprisingcaragana sinica

Human host cell for producing recombinant proteins with high quality and quantity

The present invention relates to a human host cell generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell, by using genetic engineering techniques. The human host cell with stable characteristics well preserved may be efficiently used to produce heterologous desired recombinant protein-based pharmaceuticals.

Hybrid-type multi-lamellar nanostructure of epidermal growth factor and liposome and method for manufacturing same

Pretensioner

A pretensioner for introducing a webbing wound in a spool by explosive power obtained by exploding gunpowder when an impact is applied from the outside, the pretensioner includes: a hollow cylinder having one side surface for inserting a portion of a pinion connected to the spool; a micro gas generator (MGG) mounted in an upper end portion of the cylinder and for transferring explosive power into the cylinder while gunpowder provided at the inside explodes when an impact is applied from the outside; a rack mounted in a length direction at the inside of the cylinder and having one end portion disposed toward the MGG and having the other end portion disposed opposite to the pinion and having gear teeth provided in one side surface separated not to engage with the pinion before receiving explosive power from the MGG; and a roller for receiving explosive power from the MGG and rotatably mounted at the other side surface opposite to one side surface of the cylinder in which a portion of the pinion is inserted so that the gear teeth of the rack engage with the pinion when the rack falls toward a lower end portion of the cylinder and for guiding the separated rack to move toward the pinion.

Stable pharmaceutical preparation

A stable pharmaceutical preparation according to the present invention comprises: a recombinant fusion protein; a surfactant; a saccharide or a derivative thereof; and a buffer agent. The stable pharmaceutical preparation according to the present invention has a low viscosity while comprising a recombinant fusion protein, maintains excellent stability in long-term storage, accelerated, and severe conditions, and can be intraocularly administered.

Expression cassette for preparing high expression and high performance target protein and its use

本发明涉及靶蛋白的表达盒、表达载体和转化体，表达盒包含启动子、编码该靶蛋白的多核苷酸、内含子序列和poly A序列。根据本发明的用于靶蛋白的表达盒能够通过一次转导同时进行内含子序列和靶蛋白的表达，并表现出通过调节内源基因的表达来诱导靶蛋白的高表达和高性能。

Whitening cosmetic composition comprising Caragana sinica root extract

The present invention relates to a cosmetic composition for whitening comprising a Caragana sinica root extract, and more specifically relates to a cosmetic composition having an outstanding skin-whitening effect, the composition comprising a Caragana sinica root extract, a fraction thereof or α-viniferin isolated therefrom. In the present invention, the Caragana sinica root extract, fraction thereof or α-viniferin isolated therefrom inhibits tyrosinase activity and suppresses melanin production and is therefore effective in skin whitening.

Pharmaceutical formulation comprising a xylometazoline or a salt thereof

根据本发明的包括速释层和缓释层的药物制剂具有双相溶出曲线，从而使得可以快速达到西苯唑啉的有效血浆浓度，并且随后持续保持有效血浆浓度，使得可以仅通过每天一次单次剂量给药维持西苯唑啉的药效。

Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses

The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection.

Epitope of hepatitis B virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis B virus

The present invention relates to an epitope specific to hepatitis B virus surface antigen and a binding molecule binding to the same for neutralizing hepatitis B virus. Since the epitope provided by the present invention is produced by forming a three-dimensional structure and does not comprise a determinant, by which escape mutation is induced against an administration of existing vaccines or HBIg, a composition comprising an antibody biding to the epitope or a vaccine composition comprising the epitope has a very low possibility of causing a decrease in efficacy due to escape mutation. Therefore, such an antibody or vaccine composition can be very effectively used in prevention and/or treatment of HBV.

Method for selecting a high expression recombinant cell line

The present invention relates to a method of selecting high producer clones by using an expression vector, the expression vector comprising: (i) a gene expression cassette comprising a selectable marker gene to which polyA has been inoperably linked; and (ii) a gene expression cassette which encodes a recombinant protein of interest and to which polyA has been operably linked. According to the invention, high producer clones can be selected from cell populations at least 10 times fewer than in the existing methods of selecting cell lines. Particularly, high producer clones can be selected using a low concentration of MTX compared to a conventional stepwise gene amplification strategy which comprises carrying out multiple amplification steps while increasing the concentration of MTX. Accordingly, the development period of cell lines can be shortened and the labor and cost required for selection of high-productivity cell clones can be reduced, whereby more efficient production of proteins is possible even when general selectable marker genes other than MTX are used.

Human host cell for producing recombinant proteins with high quality and quantity

Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same

The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method of producing the same and anticancer drug composition containing the same as an active ingredient.

Imatinib dichloroacetate and anti-cancer agent comprising the same

Cosmetic composition for wrinkle reduction containing gypenoside isolated fromgynostemma pentaphyllum

Composition comprising at least two influenza a virus-neutralizing-binding molecules

Load limiter

一种安装在圆柱形线轴内的负载限制器，在所述线轴上缠绕有织带，所述负载限制器用以对施加到织带上的负载进行约束，使其不会超过预设负载，所述负载限制器包括：第一扭力杆，所述第一扭力杆被插入到形成于所述线轴的中心处的中空部分中并且所述第一扭力杆的一端耦接到所述线轴的一端；以及第二扭力杆，所述第二扭力杆的一端连接到所述第一扭力杆的相对端，用以与所述第一扭力杆一起被插入到所述线轴的中空部分中，并且所述第二扭力杆的相对端耦接到安装在所述线轴的相对端上的锁具，其中所述扭力杆经配置使得所述第一扭力杆的扭转负载限制小于所述第二扭力杆的扭转负载限制。

Binding molecule having influenza a virus-neutralizing activity produced from human b cell

The present invention relates to a binding molecule having influenza A virus-neutralizing activity produced from a human B cell, and the binding molecule having the incfluenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is produced from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity with respect to the influenza A virus, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.

Binding molecule having influenza a virus-neutralizing activity produced from human b cell.

La presente invención se refiere a una molécula de unión que tiene actividad neutralizadora del virus de la influenza A, derivado de una célula B humana, y la molécula de unión que tiene la actividad neutralizadora del virus de la influenza A, de acuerdo con la presente invención, es una molécula de unión que se deriva de una célula B que está seleccionada de la sangre de un paciente infectado con un virus de influenza A y tiene actividad neutralizadora contra el virus de la influenza A y, por lo tanto, es útil para prevenir y tratar enfermedades derivadas del virus de la influenza A y puede ser útil para diagnosticar el virus de la influenza A, usando la molécula de unión de acuerdo con la presente invención.

Human host cell for producing recombinant proteins with high quality and quantity

本发明涉及一种通过使用基因工程技术使人类胚肾来源的细胞与人类B细胞来源的细胞融合产生的人类宿主细胞。具有良好保持的稳定特征的人类宿主细胞可有效地用于制造基于所需异源重组蛋白的药物。

Methods for treating TNF α -related disorders

本发明涉及一种通过皮下施用结合TNFα的抗体(抗TNFα抗体)或其抗原结合片段来治疗TNF‑α相关疾病的方法。根据本发明的治疗方法、组合物、试剂盒或用途，相较于静脉注射通过缩短施用时间和患者住院时间，从而改善患者的方便性并提高患者的生活质量，这提供了提高患者满意度的优势。

Composition comprising at least two influenza A virus-neutralizing-binding molecules

The present invention provides a composition which comprises at least two influenza A virus-neutralizing-binding molecules binding an epitope within a stem region of a hemagglutinin (HA) protein of an influenza A virus, wherein the composition comprises: i) a first binding molecule which can neutralize at least one influenza A virus subtype which is selected from the group consisting of H1, H2, H5 and H9; ii) a second binding molecule which can neutralize at least one influenza A virus subtype which is selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition of the present invention effectively neutralizes both multiple influenza subtypes of phylogeny groups 1 and 2, and can be used jointly with chemical compounds, and thus is very effective in preventing and treating disease caused by an influenza virus.

Stable peptide-conjugated ascorbic acid derivative, method for preparing same, and cosmetic composition containing same

Imatinib dichloroacetate and anti-cancer agent comprising the same

The present invention relates to imatinib dichloroacetate and an anti-cancer agent comprising the same. The imatinib dichloroacetate of the present invention can inhibit tyrosine kinase as well as induce cancer cells to kill themselves via apoptosis, thereby inhibit growth of cancer cells and lead to their destruction, and show significantly enhanced anti-cancer effects by synergy between imatinib and dichloroacetic acid.

Dosing regimen for treating influenza virus diseases

The present invention pertains to a dosing regimen for treating influenza virus diseases, and more specifically, to a method for treating influenza virus-related diseases through the administration of a mixed composition of monoclonal antibodies having a neutralizing activity against the influenza A virus. The treatment method according to the present invention enables influenza A virus-related diseases to be treated through the intravenous administration of a mixed composition of monoclonal antibodies having a neutralizing activity against the influenza A virus. In addition, the treatment method according to the present invention can satisfy unmet medical needs for biological therapeutic agents for influenza virus-related diseases.

Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof

A pharmaceutical formulation including an immediate release layer and an extended release layer according to the present disclosure has a biphasic dissolution profile, such that it is possible to quickly reach an effective plasma concentration of cibenzoline at the early stage, and the effective plasma concentration may be continuously maintained at the late stage. Therefore, the medicinal effect of cibenzoline may be maintained only by an administration of a single formulation once a day.

Stable liquid pharmaceutical preparation

OF THE DISCLOSURE The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

PHARMACEUTICAL COMPOSITION AND KIT INCLUDING ANTI-TNF ALPHA ANTIBODIES

<p><!--StartFragment-->La presente invención se refiere a una composición farmacéutica y a un kit que comprenden un anticuerpo que se une a TNF-α (anticuerpo anti-TNF-α), donde dicha composición es útil en el tratamiento de una enfermedad relacionada con TNF-α.<!--EndFragment--></p> <p> <! - StartFragment -> The present invention relates to a pharmaceutical composition and a kit comprising an antibody that binds to TNF-α (anti-TNF-α antibody), where said composition is useful in the treatment of a disease related to TNF-α. <! - EndFragment -> </p>

Varicella zoster virus fusion protein and immunogenic composition comprising same

The present invention relates to a Varicella zoster virus fusion protein and an immunogenic composition comprising same and, more specifically, to a fusion protein comprising the glycoprotein E (gE) of Varicella zoster virus (VZV) and a constant region of an immunoglobulin molecule, and an immunogenic composition comprising same. The present invention not only remarkably increases a Varicella zoster virus-specific cell-mediated immune response, but also exhibits the effect of rapidly and potently inducing an immune response and sustaining the immune response for a long period of time, compared to preexisting vaccines, thereby can be usefully used to prevent Varicella zoster-related diseases.

Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses

The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection.

Method for treating tnf alpha-related diseases

Load limiter

Disclosed is a load limiter mounted within a cylindrical spool on which a webbing is wound to constrain a load applied to the webbing from exceeding a preset load, the load limiter including: a first torsion bar inserted into a hollow portion formed at a center of the spool and one end of which is coupled to one end of the spool; and a second torsion bar one end of which is connected to an opposite end of the first torsion bar to be inserted into the hollow portion of the spool together with the first torsion bar and an opposite end of which is coupled to a locker installed at an opposite end of the spool, wherein the torsion bar is configured such that a torsion load limit of the first torsion bar is smaller than a torsion load limit of the second torsion bar.

STABLE LIQUID PHARMACEUTICAL FORMULATION

Se refiere a una formulacion farmaceutica liquida estable de baja viscosidad que contiene un anticuerpo o su fragmento de union a antigeno (su contenido es elevado, puede ser un anticuerpo que se une al factor ? de necrosis tumoral (TNF-?), infliximab, adalimumab, entre otros), un tensioactivo (polisorbato, poloxamero, o una mezcla de estos), un azucar (monosacarido, disacarido u otros) o su derivado (alcohol de azucar, acido de azucar o una mezcla de estos), y un tampon (acetato o histidina), la cual presenta una excelente estabilidad durante el almacenamiento a largo plazo (esto en base a su excelente estabilidad en condiciones aceleradas y severas), y se puede administrar por via subcutanea. Tambien se refiere a metodos de preparacion y uso de la formulacion detallada lineas arriba, asi como a metodos de tratamiento de una enfermedad relacionada con TNF-? y de estabilizacion del anticuerpo comprendido en dicha formulacion, y a productos que comprenden la formulacion y un recipiente para recibirla en un estado cerrado. La presente invencion es util para formular una composicion liquida con excelente estabilidad y alto contenido de anticuerpo, ademas que puede emplearse para el tratamiento de problemas clinicos causados por el TNF-? (en base al anticuerpo o su fragmento a usar en la formulacion). It refers to a stable, low-viscosity liquid pharmaceutical formulation that contains an antibody or its antigen-binding fragment (its content is high, it can be an antibody that binds to tumor necrosis factor? (TNF-?), Infliximab, adalimumab , among others), a surfactant (polysorbate, poloxamer, or a mixture of these), a sugar (monosaccharide, disaccharide or others) or its derivative (sugar alcohol, sugar acid or a mixture of these), and a buffer ( acetate or histidine), which has excellent stability during long-term storage (this based on its excellent stability under accelerated and severe conditions), and can be administered subcutaneously. It also refers to methods of ...

Stable liquid pharmaceutical formulation of anti-influenza virus antibody

A stable liquid pharmaceutical preparation of an anti-influenza virus antibody and, more specifically, a stable liquid pharmaceutical preparation that comprises: (A) an anti-influenza virus antibody or a mixture of two or more different types of anti-influenza virus antibodies; (B) a surfactant; (C) a sugar or a sugar derivative; and (D) an amino acid. The stable liquid pharmaceutical preparation for an anti-influenza virus antibody disclosed herein has excellent storage stability at low temperature (5° C.), room temperature (25° C.), and high temperature (40° C.) and excellent long-term (12 months) storage stability, and may be administered intravenously, intramuscularly, transdermally, subcutaneously, intraperitoneally, topically, or in combinations thereof.

Stable pharmaceutical preparation

A stable pharmaceutical preparation according to the present invention comprises: a recombinant fusion protein; a surfactant; a saccharide or a derivative thereof; and a buffer agent. The stable pharmaceutical preparation according to the present invention has a low viscosity while comprising a recombinant fusion protein, maintains excellent stability in long-term storage, accelerated, and severe conditions, and can be intraocularly administered.

含多价肺炎链球菌多糖-蛋白偶联物的免疫原性组合物、药物组合物及其用途

本发明涉及含多价肺炎链球菌多糖‑蛋白偶联物的免疫原性组合物。各偶联物包括与载体蛋白偶联的不同肺炎链球菌血清型的荚膜多糖，并因此能够诱导与Prevenar 13相比更广泛种类的血清型的免疫反应。本发明的多价免疫原性组合物能有利地用于预防婴儿、儿童和成人中因肺炎链球菌引起的疾病。

Stable liquid pharmaceutical preparation

A stable liquid pharmaceutical preparation according to the present invention contains: an antibody or an antigen-binding fragment thereof; a surfactant; a sugar or a derivative thereof; and a buffer. The stable liquid pharmaceutical preparation according to the present invention has low viscosity while containing a high amount of the antibody, has excellent long-term storage stability on the basis of excellent stability under accelerated conditions and extreme conditions, and can be administered subcutaneously.

含至少一种流感病毒的中和性结合分子的佐剂组合物及含该佐剂组合物的疫苗组合物

本发明涉及一种含有至少一种流感病毒中和性结合分子的佐剂组合物及含有其的疫苗组合物。证实了本发明的含有至少一种流感病毒中和性结合分子的所述组合物增强了疫苗效果，从而可以在施用疫苗时用作增强免疫应答的佐剂，并其对于预防由病毒引起的疾病是非常有用的。

Expressionsvektor für tierische zelle mit wenigstens einer kopie von mar-dna-sequenzen am 3'-ende des transkriptionsterminationsbereichs eines gens sowie verfahren zur expression eines fremdgens unter verwendung des vektors

Stable liquid pharmaceutical preparation

The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage ability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Stable Liquid Formula

A stable liquid formula according to the present invention comprises an antibody or an antigen-binding fragment thereof; an acetate buffer; glycine; and a surfactant, without inclusion of one or more of a saccharide, a sugar alcohol, and a metal salt, is stable even at a high content of an antibody and superior in terms of osmolality and viscosity, and can be administered subcutaneously.

Stable liquid pharmaceutical preparation

The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage ability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Clinical supplies management method and device using same

Disclosed herein a method for clinical supplies management. The method includes registering a user associated with a clinical trial according to user types, receiving a request for providing clinical supplies related to the clinical trial, receiving providing completion information for the clinical supplies, and updating clinical supplies information corresponding to the providing completion information.

Stable liquid pharmaceutical preparation for anti-influenza virus antibody

Buckle and method for preventing the buckle from being released by an impact

The present invention relates to a buckle including a frame, a tongue inserted into the frame and locked with the frame, an ejector provided in the frame to push the tongue outward from the frame, a holder that prevents the ejector from pushing the tongue outward from the frame by being displaced forward the ejector, thereby maintaining locking of the tongue, and a withdrawal prevention unit that prevents the holder from moving back beyond withdrawing and being displaced backward the ejector when an impact is applied from an outside of the frame, thereby preventing the locking of the tongue from being released by the impact.

Stabiili nestemäinen farmaseuttinen valmiste

Stabilt væskeformigt farmaceutisk præparat

Binding molecule having neutralizing activity against middle east respiratory syndrome-coronavirus

The present invention relates to a binding molecule having neutralizing activity against Middle East respiratory syndrome-coronavirus (MERS-CoV). More particularly, the present invention relates to a binding molecule having a superior ability to bind to the S protein of MERS-CoV and also having a neutralizing effect on MERS-CoV and is very useful in preventing, treating, or diagnosing MERS-CoV infection.

Stable pharmaceutical formulation

Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.

安定した薬剤学的製剤

本発明による安定した薬剤学的製剤は、組換え融合タンパク質；界面活性剤；糖またはその誘導体；および緩衝剤を含む。本発明による安定した薬剤学的製剤は、組換え融合タンパク質を含みかつ、低い粘度を有し、長期保管条件、加速条件および苛酷条件で優れた安定性を維持し、眼内投与可能である。

Stable pharmaceutical preparation

A stable pharmaceutical formulation according to the present disclosure contains: a recombinant fusion protein; a surfactant; a sugar or a derivative thereof; a buffer; and an isotonic agent. The stable pharmaceutical formulation according to the present disclosure has low viscosity while containing the recombinant fusion protein, may maintain excellent stability under long-term storage conditions, accelerated conditions and stress conditions, and may be administered intraocularly.

ＴＮＦα関連疾患の治療方法

【課題】ＴＮＦα関連疾患の治療のために、抗－ＴＮＦα抗体又はその抗原結合断片を含有する医薬組成物を対象に皮下投与する治療方法、前記医薬組成物、及び前記医薬組成物を含むキット；並びに、対象に皮下投与され、抗－ＴＮＦα抗体で治療可能な疾患を治療するための薬剤の製造における、抗－ＴＮＦα抗体又はその抗原結合断片の用途を提供する。【解決手段】本発明は、ＴＮＦαに結合する抗体（抗－ＴＮＦα抗体）又はその抗原結合断片を皮下投与し、ＴＮＦα関連疾患を治療する方法に関する。本発明に係る治療方法、組成物、キット、又は用途は、静脈注射に比べて、投与時間が短く、患者が病院に留まる時間を短縮するため、利便性を改善するとともに生活の質を向上し、よって患者の満足度を高めるという利点を提供する。【選択図】なし

Preparação farmacêutica líquida estável

Immunogenic Composition Comprising Multivalent Streptococcus Pneumoniae Polysaccharide-Protein Conjugates

The present invention relates to an immunogenic composition including multivalent pneumococcal polysaccharide-protein conjugates. Each conjugate includes capsular polysaccharides of different pneumococcus serotypes conjugated to a carrier protein. More concretely, the present invention is a multivalent immunogenic composition including polysaccharide-protein conjugates. Each of the polysaccharide-protein conjugates includes Streptococcus pneumoniae-derived capsular polysaccharides of different serotypes conjugated to a carrier protein. The capsular polysaccharides include a) capsular polysaccharides of one or more serotypes selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and b) capsular polysaccharides of one or more serotypes selected from the group consisting of serotypes 10A, 11A, 12F, 15B, 22F, 23A, and 35B. The multivalent immunogenic composition according to the present invention is capable of inducing an immune reaction against a wider variety of serotypes than the conventional Prevenar 13. In particular, the conventional Prevenar 13 is designed mainly for serotypes frequently appearing in Europe and North America, but the immunogenic composition of the present invention is an immunogenic composition having high coverage not only in Europe and North America but also throughout Asia. Therefore, the multivalent immunogenic composition according to the present invention is capable of being beneficially used to prevent diseases caused by pneumococcus in infants, children, and adults.

Immunogenic composition comprising multivalent streptococcus pneumoniae polysaccharide-protein conjugates

The present invention relates to an immunogenic composition including multivalent pneumococcal polysaccharide-protein conjugates. Each conjugate includes capsular polysaccharides of different pneumococcus serotypes conjugated to a carrier protein. More concretely, the present invention is a multivalent immunogenic composition including polysaccharide-protein conjugates. Each of the polysaccharide-protein conjugates includes Streptococcus pneumoniae-derived capsular polysaccharides of different serotypes conjugated to a carrier protein. The capsular polysaccharides include a) capsular polysaccharides of one or more serotypes selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and b) capsular polysaccharides of one or more serotypes selected from the group consisting of serotypes 10A, 11A, 12F, 15B, 22F, 23A, and 35B. The multivalent immunogenic composition according to the present invention is capable of inducing an immune reaction against a wider variety of serotypes than the conventional Prevenar 13. In particular, the conventional Prevenar 13 is designed mainly for serotypes frequently appearing in Europe and North America, but the immunogenic composition of the present invention is an immunogenic composition having high coverage not only in Europe and North America but also throughout Asia. Therefore, the multivalent immunogenic composition according to the present invention is capable of being beneficially used to prevent diseases caused by pneumococcus in infants, children, and adults.

带扣以及防止由于碰撞而使带扣松开的方法

本发明涉及一种带扣，所述带扣包括：框架；舌片，插入所述框架内并与所述框架扣在一起；顶出器，配备在所述框架内以将所述舌片向所述框架的外边推；固定器，通过在所述顶出器前面设置所述固定器以防止所述顶出器将所述舌片向所述框架外边推，从而保持所述舌片的扣住状态；以及防脱单元，当从所述框架外部施加碰撞时防止所述固定器脱出并且设置在所述顶出器的后面，从而防止由于碰撞而使扣住的所述舌片松开。

Stable liquid pharmaceutical preparation

Stabilan tečni farmaceutski preparat

Stabilus skystas vaistinis preparatas

Stable liquid pharmaceutical preparation

The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition

The present invention relates to a pharmaceutical composition comprising S(-)-cibenzoline or a pharmaceutically acceptable salt thereof as an active ingredient for treatment of hypertrophic cardiomyopathy, and a method for treatment of hypertrophic cardiomyopathy by using same.

治疗肥厚型心肌病的药物组合物和使用该组合物的治疗方法

本发明涉及一种用于治疗肥厚型心肌病的药物组合物以及使用其治疗肥厚型心肌病的方法，所述药物组合物包含S(‑)‑西苯唑啉或其药学上可接受的盐作为活性成分。

Buckle and method for preventing the buckle from being released by an impact

The present invention relates to a buckle including a frame, a tongue inserted into the frame and locked with the frame, an ejector provided in the frame to push the tongue outward from the frame, a holder that prevents the ejector from pushing the tongue outward from the frame by being displaced forward the ejector, thereby maintaining locking of the tongue, and a withdrawal prevention unit that prevents the holder from moving back beyond withdrawing and being displaced backward the ejector when an impact is applied from an outside of the frame, thereby preventing the locking of the tongue from being released by the impact.

安定した薬剤学的製剤

本発明による安定した薬剤学的製剤は、（Ａ）インターロイキン－６受容体（Ｉｎｔｅｒｌｅｕｋｉｎ－６ ｒｅｃｅｐｔｏｒ）に結合する抗体またはその抗原結合断片；（Ｂ）界面活性剤；（Ｃ）安定化剤；および（Ｄ）緩衝剤を含む。本発明による安定した薬剤学的製剤は、抗体を含み、特に抗体を高濃度で含む場合にも、低い粘度を有し、加速条件および苛酷条件での優れた安定性に基づいて長期間保管安定性に優れ、静脈または皮下投与が可能である。【選択図】図１

Stable pharmaceutical preparation

Método para tratar doenças relacionadas a tnfa

método para tratar doenças relacionadas a tnfa. a presente prevenção se refere a métodos para tratar doenças relacionadas a tnfa administrando-se subcutaneamente um anticorpo que se liga a tnfa (anticorpo anti-tnfa) ou um fragmento de ligação a antígeno do mesmo. o método de tratamento, composição, kit ou uso, de acordo com a presente invenção, fornece uma vantagem de aprimorar a satisfação do paciente, aprimorando-se a conveniência e a qualidade de vida, isto é, reduzindo-se o tempo exigido para administração e diminuição da duração de permanência de pacientes em um hospital em comparação com a injeção intravenosa.

Cosmetic composition for wrinkle reduction containing gypenoside isolated from gynostemma pentaphyllum

Stable liquid formula comprising anti-TNFa antibody, acetate buffer, and glycine

Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Binding molecule having neutralizing activity against middle east respiratory syndrome coronavirus

The present invention relates to a binding molecule having neutralizing activity against Middle East respiratory syndrome-coronavirus (MERS-CoV). More particularly, the present invention relates to a binding molecule having a superior ability to bind to the S protein of MERS-CoV and also having a neutralizing effect on MERS-CoV and is very useful in preventing, treating, or diagnosing MERS-CoV infection.